SCHEMBL12866839

SCHEMBL12866839

CC(C)(C)Cc1cccc(-c2ccccc2C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 5/20 0.47
▸ FFAR1 O14842 3/20 0.45
▸ AR P10275 1/20 0.44
▸ TRPA1 O75762 3/20 0.42
▸ BACE1 P56817 1/20 0.40
▸ TRPM8 Q7Z2W7 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ HSD11B1 P28845 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ PTPN5 P54829 1/20 0.40
▸ USP2 O75604 1/20 0.39
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12881755 0.84 SCN9A (0.47) SCN9AFFAR1ARTRPA1BACE1
SCHEMBL18015814 0.84 SCN9A (0.49) SCN9AFFAR1ARTRPA1BACE1
SCHEMBL12866833 0.81 DRD2 (0.48) FFAR1HTR7
SCHEMBL3727424 0.81 SCN9A (0.49) SCN9AFFAR1ARTRPA1BACE1
SCHEMBL27705791 0.78 AR (0.55) SCN9AFFAR1ARTRPA1BACE1
SCHEMBL4699892 0.78 FFAR1 (0.47) SCN9AFFAR1ARTRPA1BACE1
SCHEMBL12866824 0.78 AOC3 (0.49) SCN9AFFAR1ARCLK4HTR7
SCHEMBL197793 0.77 GGPS1 (0.44) —
SCHEMBL18014710 0.77 KIF11 (0.53) FFAR1
SCHEMBL18014711 0.76 SCN8A (0.40) FFAR1BACE1CLK4HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046160-A1 Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases PFIZER, INC. 2011-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046160-A1 Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases SNCA, PARK7, HTT SCN9A 515/4885FFAR1 2024/4885AR 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback